Comparison: Tocilizumab versus placebo or standard care

Outcome	No. of studies	No. Of participants	Statistical method	Effect size
Clinical improvement D28	7	5585	Risk Ratio (M-H, Random, 95% CI)	1.06 (1.00 to 1.13)
WHO progression score (level 7 or above) D28	3	712	Risk Ratio (M-H, Random, 95% CI)	0.99 (0.56 to 1.74)
All-cause mortality D28	8	6363	Risk Ratio (M-H, Random, 95% CI)	0.89 (0.82 to 0.97)
All-cause mortality D60	2	519	Risk Ratio (M-H, Random, 95% CI)	0.86 (0.53 to 1.40)
Adverse events	7	1534	Risk Ratio (M-H, Random, 95% CI)	1.23 (0.87 to 1.72)
Serious adverse events	8	2312	Risk Ratio (M-H, Random, 95% CI)	0.89 (0.75 to 1.06)
Time to clinical improvement	6	2118	Hazard Ratio (95% CI)	1.23 (1.08 to 1.39)
Time to WHO progression score (level 7 and above)	3	762	Hazard Ratio (95% CI)	0.62 (0.42 to 0.91)
Time to death	3	1152	Hazard Ratio (95% CI)	0.65 (0.51 to 0.83)

Analysis 1.1.1 Tocilizumab versus placebo or standard care. Outcome: Clinical improvement 28



Analysis 1.1.2 Tocilizumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28



Analysis 1.1.3 Tocilizumab versus placebo or standard care. Outcome: All-cause mortality D28



Analysis 1.1.4 Tocilizumab versus placebo or standard care. Outcome: All-cause mortality D60



Analysis 1.1.5 Tocilizumab versus placebo or standard care. Outcome: Adverse events



Analysis 1.1.6 Tocilizumab versus placebo or standard care. Outcome: Serious adverse events



Analysis 1.2.1 Tocilizumab versus placebo or standard care. Outcome: Time to clinical improvement

N1: Number of participants randomized to intervention 1

N2: Number of participants randomized to intervention 2



Analysis 1.2.2 Tocilizumab versus placebo or standard care. Outcome: Time to WHO progression score (level 7 and above)

N1: Number of participants randomized to intervention 1

N2: Number of participants randomized to intervention 2



Analysis 1.2.3 Tocilizumab versus placebo or standard care. Outcome: Time to death

N1: Number of participants randomized to intervention 1

N2: Number of participants randomized to intervention 2



Subgroup analysis. 1.3.1 Funding. Tocilizumab versus placebo or standard care. Outcome: Clinical improvement D28



Subgroup analysis.1.3.2 Funding. Tocilizumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28



Subgroup analysis.1.3.3 Funding. Tocilizumab versus placebo or standard care. Outcome: All-cause mortality D28



Subgroup analysis. 1.3.4 Funding. Tocilizumab versus placebo or standard care. Outcome: All-cause mortality D60



Subgroup analysis. 1.3.5 Funding. Tocilizumab versus placebo or standard care. Outcome: Adverse events



Subgroup analysis. 1.3.6 Funding. Tocilizumab versus placebo or standard care. Outcome: Serious adverse events



Subgroup analysis. 1.4.1 Location. Tocilizumab versus placebo or standard care. Outcome: Clinical improvement D28



Subgroup analysis. 1.4.2 Location. Tocilizumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28



Subgroup analysis.1.4.3 Location. Tocilizumab versus placebo or standard care. Outcome: All-cause mortality D28



Subgroup analysis. 1.4.4 Location. Tocilizumab versus placebo or standard care. Outcome: All-cause mortality D60



Subgroup analysis. 1.4.5 Location. Tocilizumab versus placebo or standard care. Outcome: Adverse events



Subgroup analysis. 1.4.6 Location. Tocilizumab versus placebo or standard care. Outcome: Serious adverse events



Subgroup analysis. 1.5.1 Conflict of Interests. Tocilizumab versus placebo or standard care. Outcome: Clinical improvement D28



Subgroup analysis. 1.5.2 Conflict of Interests. Tocilizumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28



Subgroup analysis. 1.5.3 Conflict of Interests. Tocilizumab versus placebo or standard care. Outcome: All-cause mortality D28



Subgroup analysis. 1.5.4 Conflict of Interests. Tocilizumab versus placebo or standard care. Outcome: All-cause mortality D60



Subgroup analysis. 1.5.5 Conflict of Interests. Tocilizumab versus placebo or standard care. Outcome: Adverse events



Subgroup analysis. 1.5.6 Conflict of Interests. Tocilizumab versus placebo or standard care. Outcome: Serious Adverse events



Sensitivity analysis 1.6.1 Published studies. Tocilizumab versus placebo or standard care. Outcome: Clinical Improvement D28. Published studies.



Sensitivity analysis 1.6.2 Published studies. Tocilizumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28.



Sensitivity analysis 1.6.3 Published studies. Tocilizumab versus placebo or standard care. Outcome: All-cause mortality D28.



Sensitivity analysis 1.6.4 Published studies. Tocilizumab versus placebo or standard care. Outcome: Adverse events.



Sensitivity analysis 1.6.5 Published studies. Tocilizumab versus placebo or standard care. Outcome: Serious adverse events.



Sensitivity analysis 1.7.1 Without studies at High risk of Bias. Tocilizumab versus placebo or standard care. Outcome: Adverse events.



Sensitivity analysis 1.7.2 Without studies at High risk of Bias. Tocilizumab versus placebo or standard care. Outcome: Serious adverse events.



Sensitivity analysis 1.8.1 Severity. Tocilizumab versus placebo or standard care. Outcome: Clinical Improvement D28.



Sensitivity analysis 1.8.2 Severity. Tocilizumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28.



Sensitivity analysis 1.8.3 Severity. Tocilizumab versus placebo or standard care. Outcome: All-cause mortality D28.



Sensitivity analysis 1.8.4 Severity. Tocilizumab versus placebo or standard care. Outcome: Adverse events.



Sensitivity analysis 1.8.5 Severity. Tocilizumab versus placebo or standard care. Outcome: Serious Adverse events.



Sensitivity analysis 1.9.1 Participants analyzed. Tocilizumab versus placebo or standard care. Outcome: Clinical Improvement D28.



Sensitivity analysis 1.9.2 Participants analyzed. Tocilizumab versus placebo or standard care. Outcome: WHO progression score (level 7 or above) D28.



Sensitivity analysis 1.9.3 Participants analyzed. Tocilizumab versus placebo or standard care. Outcome: All-cause mortality D28.



Sensitivity analysis 1.9.4 Participants analyzed. Tocilizumab versus placebo or standard care. Outcome: All-cause mortality D60.



Sensitivity analysis 1.9.5 Participants analyzed. Tocilizumab versus placebo or standard care. Outcome: Adverse events.



Sensitivity analysis 1.9.6 Participants analyzed. Tocilizumab versus placebo or standard care. Outcome: Serious Adverse events.



Comparison: Sarilumab versus placebo or standard care

Outcome	No. of studies	No. Of participants	Statistical method	Effect size
All-cause mortality D28	2	880	Risk Ratio (M-H, Random, 95% CI)	0.77 (0.43 to 1.36)
All-cause mortality D60	1	420	Risk Ratio (M-H, Random, 95% CI)	1.00 (0.50 to 2.00)
Adverse events	1	420	Risk Ratio (M-H, Random, 95% CI)	1.05 (0.88 to 1.25)
Serious adverse events	2	880	Risk Ratio (M-H, Random, 95% CI)	1.17 (0.77 to 1.77)
Time to clinical improvement	2	880	Hazard Ratio (95% CI)	1.28 (0.88 to 1.87)
Time to death	1	460	Hazard Ratio (95% CI)	0.55 (0.33 to 0.91)

Analysis 2.1.1 Sarilumab versus placebo or standard care. Outcome: All-cause mortality D28



Analysis 2.1.2 Sarilumab versus placebo or standard care. Outcome: All-cause mortality D60



Analysis 2.1.3 Sarilumab versus placebo or standard care. Outcome: Adverse events



Analysis 2.1.4 Sarilumab versus placebo or standard care. Outcome: Serious adverse events



Analysis 2.2.1 Sarilumab versus placebo or standard care. Outcome: Time to clinical improvement

N1: Number of participants randomized to intervention 1

N2: Number of participants randomized to intervention 2



Analysis 2.2.2 Sarilumab versus placebo or standard care. Outcome: Time to death

N1: Number of participants randomized to intervention 1

N2: Number of participants randomized to intervention 2